Operating Lease, Right-of-Use Asset of Amphastar Pharmaceuticals, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Amphastar Pharmaceuticals, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Amphastar Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $44,577,000, a 41% increase year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Amphastar Pharmaceuticals, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $44,577,000 +$12,869,000 +41% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $44,199,000 +$12,095,000 +38% 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $45,822,000 +$14,470,000 +46% 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $46,899,000 +$14,566,000 +45% 31 Dec 2024 10-Q 06 Nov 2025 2025 Q3
Q3 2024 $31,708,000 -$958,000 -2.9% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $32,104,000 +$5,777,000 +22% 30 Jun 2024 10-Q 09 Aug 2024 2024 Q2
Q1 2024 $31,352,000 +$5,551,000 +22% 31 Mar 2024 10-Q 10 May 2024 2024 Q1
Q4 2023 $32,333,000 +$6,779,000 +27% 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $32,666,000 +$6,210,000 +23% 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 $26,327,000 -$635,000 -2.4% 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $25,801,000 -$2,042,000 -7.3% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $25,554,000 -$1,340,000 -5% 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $26,456,000 -$1,207,000 -4.4% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $26,962,000 -$207,000 -0.76% 30 Jun 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 $27,843,000 +$8,563,000 +44% 31 Mar 2022 10-Q 10 May 2022 2022 Q1
Q4 2021 $26,894,000 +$6,852,000 +34% 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 $27,663,000 +$7,407,000 +37% 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $27,169,000 +$10,083,000 +59% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $19,280,000 +$1,346,000 +7.5% 31 Mar 2021 10-Q 07 May 2021 2021 Q1
Q4 2020 $20,042,000 +$1,237,000 +6.6% 31 Dec 2020 10-K 11 Mar 2022 2021 FY
Q3 2020 $20,256,000 +$793,000 +4.1% 30 Sep 2020 10-Q 06 Nov 2020 2020 Q3
Q2 2020 $17,086,000 -$3,057,000 -15% 30 Jun 2020 10-Q 07 Aug 2020 2020 Q2
Q1 2020 $17,934,000 +$4,454,000 +33% 31 Mar 2020 10-Q 11 May 2020 2020 Q1
Q4 2019 $18,805,000 31 Dec 2019 10-K 15 Mar 2021 2020 FY
Q3 2019 $19,463,000 30 Sep 2019 10-Q 08 Nov 2019 2019 Q3
Q2 2019 $20,143,000 30 Jun 2019 10-Q 09 Aug 2019 2019 Q2
Q1 2019 $13,480,000 31 Mar 2019 10-Q 10 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.